Zocor is indicated to reduce mortality due to coronary artery disease. It is prescribed for the reduction of risk of serious vascular and coronary complications: non-fatal myocardial infarction, coronary death, stroke; revascularization operations. Designed to reduce the risk of the need for coronary blood flow restoration; rot reduce the risk of the need for surgical intervention to restore peripheral blood flow and other types of non-coronary revascularization; to reduce the risk of hospitalization in connection with attacks of angina pectoris; to decrease in the elevated level of total cholesterol, LDL cholesterol, triglycerides. apolipoprotein B; for increasing HDL cholesterol in patients with primary hypercholesterolemia, including heterozygous familial hypercholesterolemia.

Uroxatral - Alfuzosinis an active substance, as an antagonist of the α1 adenogenetic receptor, this drug relaxes the muscles of the prostate and the bladder. Used in the treatment of benign prostatic hyperplasia (BPH). Reduces pressure in the urethra and reduces resistance to urine flow, eases urination and eliminates dysuria.

Blocks the final stage of HCl secretion, reducing basal and stimulated secretion, regardless of the nature of the stimulus. Prescribed for gastric ulcer and duodenal ulcer in acute phase, erosive-ulcerative esophagitis, reflux esophagitis, Zollinger-Ellison syndrome, stress ulcers of the gastrointestinal tract; eradication of Helicobacter pylori within a combination therapy, non-ulcer dyspepsia.